Mojawapo ya njia za mwisho zinazofanana katika kuendelea kwa ugonjwa sugu wa figo hadi kushindwa kwa figo ni fibrosis ya figo. Wakati wa fibrosis, tishu ya kawaida ya figo hubadilishwa hatua kwa hatua na collagen na vipengele vingine vya extracellular matrix; usanifu wa tishu unaofanya kazi huharibika na uwezo wa figo kuchuja hupungua. Mchakato huu hauwezi kuelezwa kwa shughuli nyingi za fibroblast pekee. Metabolism ya seli, seli za tubule za figo, seli za kinga na ishara za uchochezi huunda microenvironment inayojilisha yenyewe.

Utafiti unaochambuliwa unapendekeza mekanizimu inayoeleza jinsi mabadiliko ya kimetaboliki katika jeraha sugu la figo yanavyogeuka kuwa mwitikio wa kinga wa muda mrefu na fibrosis. Kwa mujibu wa watafiti, katika figo iliyojeruhiwa hexosamine biosynthesis pathway, yaani HBP, huamilishwa na kuongeza uzalishaji wa UDP-GlcNAc ndani ya seli. UDP-GlcNAc ni substrate kuu inayotumiwa kuongeza O-linked N-acetylglucosamine kwenye protini.

Mekanizimu ya jumla inayopendekezwa inaweza kufupishwa hivi:

\[ \mathrm{HBP}\uparrow \rightarrow \mathrm{UDP\!-\!GlcNAc}\uparrow \rightarrow \mathrm{STAT3\!-\!T717\ O\!-\!GlcNAc}\uparrow \rightarrow \mathrm{SMURF1\ bağlanması}\downarrow \rightarrow \mathrm{STAT3\ yıkımı}\downarrow \]

\[ \mathrm{STAT3\ kararlılığı}\uparrow \rightarrow \mathrm{CXCL10}\uparrow \rightarrow \mathrm{CD4^+\ T\ hücresi\ göçü}\uparrow \rightarrow \mathrm{Th17/IL\!-\!17A}\uparrow \rightarrow \mathrm{böbrek\ fibrozisi}\uparrow \]

Katika data za binadamu wenye ugonjwa sugu wa figo, mabadiliko makubwa ya expression ya OGT na OGA hayakuonekana, ilhali enzymes kuu za HBP — GFPT1, GNPNAT1, PGM3 na UAP1 — ziliripotiwa kuongezeka. Viwango vya jumla vya protein O-GlcNAc vilionekana kuwa juu katika biopsies za figo za binadamu na katika modeli mbili tofauti za panya.

Modeli mbili za fibrosis zilizotumika kwa panya ni:

• Unilateral ureteral obstruction iliyosababishwa kwa kufunga ureter — UUO
• Folic acid nephropathy iliyosababishwa kwa sindano ya 250 mg/kg folic acid — FA

DON, iliyotumika kukandamiza GFPT1, enzyme ya rate-limiting ya HBP, ilipunguza O-GlcNAc kwenye figo za panya; pia ilipunguza fibrosis markers kama collagen I na α-SMA, mkusanyiko wa collagen kwenye histolojia na infiltration ya seli za uchochezi. Uboreshaji wa serum creatinine na blood urea nitrogen pia uliripotiwa.

Katika RNA sequencing, genes 97 zilipatikana ambazo ziliongezeka pamoja na jeraha la figo na zikashuka tena baada ya DON. Genes hizi zilihusishwa na chemokine receptor activity, T-cell migration na immune responses. Hasa axis ya CXCL10–CXCR3 ilijitokeza kama kiungo kikuu katika kuvuta CD4+ T cells kwenda figoni.

Kuongeza kiwango cha O-GlcNAc kuliongeza expression ya CXCL10 katika renal tubular cells. Kutumia CXCR3 antagonist AMG487 kulipunguza infiltration ya CD4+ T cells, fibrosis markers na kuzorota kwa kidney function.

Hatua ya pili ya kinga ni Th17 cells. Flow cytometry ilipima uwiano wa IL-17A-producing Th17 cells kati ya live CD4+ T cells ndani ya figo. Kukandamiza HBP kwa DON kulipunguza uwiano wa Th17 na kiwango cha IL-17A figoni. Neutralization ya moja kwa moja ya IL-17 kwa secukinumab pia ilipunguza jeraha na fibrosis katika animal model.

Majaribio ya molekuli yanaweka protein ya STAT3 katikati ya mabadiliko haya ya kimetaboliki na kinga. Watafiti waliripoti kwamba kuongezwa kwa O-GlcNAc kwenye threonine 717, yaani T717 ya STAT3, huongeza muda ambao protini hubaki ndani ya seli. Modification hii haikuongeza STAT3 kwenye kiwango cha gene; ilizuia degradation ya protini.

Katika hali ya kawaida, E3 ubiquitin ligase inayoitwa SMURF1 inapendekezwa kufunga STAT3 na kurahisisha ubiquitination yake na kuvunjwa na proteasome. O-GlcNAc inapoongezwa T717, binding ya SMURF1 kwa STAT3 hupungua, STAT3 huubiquitinate kidogo na hubaki ndani ya seli kwa muda mrefu zaidi.

\[ \mathrm{STAT3 + SMURF1} \rightarrow \mathrm{STAT3\!-\!Ub_n} \rightarrow \mathrm{proteazomal\ yıkım} \]

O-GlcNAc modification huzuia hatua ya kwanza ya mlolongo huu na kufanya STAT3 iwe stable. Katika STAT3-T717A mutant, ambapo T717 imebadilishwa kuwa alanine, protein half-life iliripotiwa kuwa fupi na ubiquitination kuwa juu zaidi.

Watafiti kisha walifanya structure-based virtual screening kutafuta compounds zinazoweza kulenga T717 ya STAT3. Compounds 3.158 kutoka “FDA-approved compound library” ziliscreeniwa; candidates 38 zilichaguliwa na inositol nicotinate, saquinavir na rutin hydrate zilizokuwa juu zaidi katika ranking zikajaribiwa kwa maabara.

Kati ya candidates hizi tatu, rutin hydrate pekee iliripotiwa kupunguza STAT3 O-GlcNAc modification na protein level ya STAT3. Rutin hydrate haikubadilisha STAT3 mRNA, lakini ilipunguza CXCL10 expression. Kutokuwepo kwa athari ileile kwenye STAT3 yenye T717 mutation kulitafsiriwa na waandishi kama data inayounga mkono mechanism inayotegemea T717.

Katika UUO mice, oral rutin hydrate ya 5 mg/kg/gün ilipunguza STAT3 na phosphorylated STAT3, infiltration ya CD4+ T cells, Th17 differentiation, kidney injury markers na histological fibrosis. Uboreshaji wa serum creatinine na BUN pia uliripotiwa.

Matokeo haya hayaonyeshi kwamba rutin hydrate inatibu ugonjwa sugu wa figo kwa binadamu. Findings zinatokana na cell culture na small animal groups. Absorption kwa binadamu, dozi inayofaa, usalama kwa wagonjwa wa figo, long-term toxicity na clinical efficacy havijachunguzwa.

Tatizo kuu la utafiti ni lipi?

Ugonjwa sugu wa figo unaweza kuanza kutokana na sababu tofauti: hypertension, metabolic diseases, immune injury, toxic effects au recurrent acute kidney injury. Licha ya sababu kuwa tofauti, katika ugonjwa unaoendelea huonekana mwisho mmoja wa pathological: renal fibrosis.

Katika fibrosis:

• tishu ya kawaida ya figo hujeruhiwa,
• myofibroblast-like cells huamilishwa,
• collagen na extracellular matrix hujikusanya,
• renal tubules na maeneo ya karibu na mishipa hufanyiwa remodeling,
• idadi ya functional nephrons hupungua.

Inflammatory na hemodynamic mechanisms zinazojulikana zinaeleza sehemu tu ya mchakato. Pengo linalolengwa ni jinsi mabadiliko ya cellular metabolism yanavyogeuka kuwa persistent immune response na jinsi response hiyo inavyoendeleza fibrosis.

Hexosamine biosynthesis pathway ni nini?

Hexosamine biosynthesis pathway ni tawi dogo lakini muhimu la glucose metabolism. Huunganisha inputs kutoka glucose, glutamine, fatty acid na nucleotide metabolism ili kuzalisha UDP-GlcNAc.

Kwa kueleza mantiki ya utafiti, mtiririko rahisi unaweza kuonyeshwa:

\[ \mathrm{Fruktoz\!-\!6\!-\!fosfat + Glutamin} \xrightarrow{\mathrm{GFPT1}} \mathrm{Glukozamin\!-\!6\!-\!fosfat} \]

\[ \mathrm{Glukozamin\!-\!6\!-\!fosfat} \xrightarrow{\mathrm{GNPNAT1,\ PGM3,\ UAP1}} \mathrm{UDP\!-\!GlcNAc} \]

Milinganyo hii haikuandikwa kama reaction sequence moja katika makala; imeonyeshwa ili kufanya functional order ya HBP enzymes iwe rahisi kuelewa.

Enzymes kuu za HBP zilizochunguzwa ni:

HBP si njia ya kuzalisha nishati tu. Hubadilisha nutritional na stress status ya seli kuwa chemical signal inayoweza kubadilisha function ya proteins.

O-GlcNAc modification ni nini?

O-GlcNAc modification ni kuongezwa kwa N-acetylglucosamine group moja kwenye serine au threonine residues za intracellular proteins. Kama phosphorylation, ni njia ya haraka na reversible ya protein regulation.

O-GlcNAc transferase, yaani OGT, huongeza sugar group kwenye protein:

\[ \mathrm{Protein\!-\!OH + UDP\!-\!GlcNAc} \xrightarrow{\mathrm{OGT}} \mathrm{Protein\!-\!O\!-\!GlcNAc + UDP} \]

O-GlcNAcase, yaani OGA, huiondoa:

\[ \mathrm{Protein\!-\!O\!-\!GlcNAc} \xrightarrow{\mathrm{OGA}} \mathrm{Protein\!-\!OH + GlcNAc} \]

Milinganyo hii ya msingi imetolewa kueleza mantiki ya biochemical ya utafiti.

O-GlcNAc kwenye protein inaweza kubadilisha:

• mahali protein ilipo ndani ya seli,
• interaction na proteins nyingine,
• activity,
• phosphorylation,
• ubiquitination,
• half-life.

vinaweza kubadilika.

Ugunduzi wa kwanza: Tatizo linaweza kuwa substrate flux zaidi kuliko kiasi cha OGT/OGA

Katika Nephroseq data za CKD ya binadamu, expression ya OGT na OGA haikutofautiana kwa maana na healthy kidney, ilhali GFPT1, GNPNAT1, PGM3 na UAP1 ziliongezeka.

Immunohistochemistry ya human CKD biopsies ilionyesha kuongezeka kwa general O-GlcNAc. Figure legend inatoa n = 20 kwa analysis hii, lakini distribution ya samples kulingana na CKD stage au healthy controls haijaelezwa kwa kina.

Katika UUO na folic acid nephropathy pia:

• mRNA levels za HBP enzymes ziliongezeka,
• protein levels za HBP enzymes ziliongezeka,
• general O-GlcNAc modification iliongezeka,
• OGT expression haikubadilika kwa uwazi.

Waandishi wanaeleza pattern hii kwa kuongezeka kwa HBP flux na UDP-GlcNAc substrate supply.

Tofauti muhimu: OGT na OGA expression kutobadilika hakuthibitishi kwamba catalytic activity zao hazijabadilika. Utafiti ulitazama amount/expression, lakini direct enzyme activity haijaripotiwa katika main text. Hivyo data zinaunga mkono HBP kama explanation yenye nguvu bila kufunga kabisa uwezekano wa contribution ya OGT au OGA activity.

Uhusiano na kidney function katika data ya binadamu

GFPT1, PGM3 na GNPNAT1 expression ziliripotiwa kuhusiana na glomerular filtration iliyoharibika zaidi. Uhusiano huo haukuonekana kwa OGT na OGA.

Figure 2 legend ilifafanua impaired kidney function kama:

\[ \mathrm{GFR} < 60\ \mathrm{mL/dakika/1{,}73\ m^2} \]

.

Data hii ni observational. High HBP enzyme inaweza kusababisha kidney dysfunction; kidney injury inaweza kuongeza HBP enzymes; au mabadiliko yote mawili yanaweza kusababishwa na process nyingine. Causality ilichunguzwa katika animal na cell experiments.

Animal model ya kwanza: Unilateral ureter obstruction

Kwa male BALB/c mice wenye wiki 8–10, left ureter ilifungwa katika sehemu mbili na kukatwa katikati. Control animals walifanyiwa procedure ileile bila kufunga ureter. Figo zilikusanywa siku saba baada ya upasuaji.

UUO husababisha haraka tubulointerstitial injury, inflammation na fibrosis. Haijumuishi sababu zote za human CKD; ni model ya experimental fibrosis kwa muda mfupi.

Animal model ya pili: Folic acid nephropathy

Male BALB/c mice walipewa:

\[ 250\ \mathrm{mg/kg\ folik\ asit} \]

kwa single intraperitoneal dose. Controls walipokea vehicle tu. Wanyama walitathminiwa siku ya 28.

Folic acid model husababisha tubular injury, inflammation na fibrosis kwa muda. Kutumia modeli mbili kunaunga mkono kwamba mechanism si maalum kwa ureter obstruction. Hata hivyo, zote mbili hazinakili kikamilifu human CKD inayoendelea kwa miaka na factors nyingi.

Kukandamiza HBP kwa DON

6-diazo-5-oxo-L-norleucine, yaani DON, ilitumika kukandamiza GFPT1 na HBP flux:

\[ 20\ \mathrm{mg/kg/gün,\ intraperitoneal} \]

Baada ya DON:

• renal O-GlcNAc ilipungua,
• collagen I ilipungua,
• α-SMA ilipungua,
• collagen deposition kwenye Masson stain ilipungua,
• tissue injury na inflammatory infiltration kwenye PAS stain vilipungua,
• serum creatinine na BUN elevation zilipungua.

Kwa kuwa matokeo haya yalijirudia katika UUO na FA, waandishi walihitimisha kwamba HBP-driven O-GlcNAc increase inachangia fibrosis na loss of kidney function.

Hata hivyo, main text inaonyesha pharmacological HBP inhibition tu. Hakuna kidney-cell-specific genetic deletion au overexpression ya GFPT1 iliyoripotiwa. Hivyo si sahihi kusema effects zote za DON lazima zipitie GFPT1 pekee.

RNA sequencing ilionyesha pathway gani?

Transcriptome analysis ilifanywa katika UUO, sham na DON-treated UUO kidneys. Genes 97 zilizopanda na kidney injury na kushuka tena kwa DON zilitambuliwa.

Gene Ontology ilionyesha:

• C-X-C chemokine receptor activity,
• immune responses,
• T-cell-related signaling.

Cd4, Cxcr3 na Cxcr6 zilitajwa kuwa core genes. KEGG ilionyesha enrichment ya pathways zinazohusiana na Th17 differentiation.

Cd4, Cxcr3 na Cxcr6 ziliripotiwa miongoni mwa genes kuu. KEGG analysis nayo ilionyesha enrichment ya pathways zinazohusiana na Th17 cell differentiation.

CXCL10–CXCR3 axis hufanya nini?

CXCL10 ni chemokine inayovuta immune cells fulani kuelekea injured tissue kupitia chemical gradient. CXCR3 ni receptor inayopatikana hasa kwenye activated T cells.

Cellular flow inayopendekezwa ni:

\[ \mathrm{Böbrek\ tübül\ hücresi\ CXCL10}\uparrow \rightarrow \mathrm{CXCR3^+\ CD4^+\ T\ hücresi\ göçü}\uparrow \]

DON ilipunguza Cxcl10 na Cd4 mRNA na CD4+ T-cell infiltration figoni.

Katika HK-2 human proximal tubular cells, kuongeza O-GlcNAc kwa OGA inhibitor Thiamet G kuliongeza CXCL10 expression. Hii inaonyesha kwamba O-GlcNAc inaweza kuathiri renal epithelial cells zinazovuta immune cells, si immune cells pekee.

AMG487 experiment ilijaribu nini?

Kupima functional role ya CXCR3, UUO mice walipewa:

\[ 5\ \mathrm{mg/kg/gün\ AMG487,\ intraperitoneal} \]

.

CXCR3 antagonism:

• ilipunguza kuingia kwa CD4+ T cells figoni,
• ilipunguza collagen I na α-SMA,
• iliboresha serum creatinine na BUN.

Experiment hii inaunga mkono kwamba CXCL10–CXCR3 axis si RNA signature tu, bali ina functional contribution kwa fibrotic phenotype.

Kwa nini Th17 cells ni muhimu?

Th17 cells ni CD4+ helper T cells zinazotoa inflammatory cytokines, hasa IL-17A. Wakati wa kidney injury, signal zake zinaweza:

• kuongeza stress na injury katika epithelial cells,
• kuongeza profibrotic factors kama TGF-β,
• kusaidia epithelial-to-mesenchymal-like changes,
• kuharakisha extracellular matrix deposition.

Katika flow cytometry, Th17 zilifafanuliwa kama IL-17A-positive cells ndani ya live CD4+ T lymphocyte gate:

\[ \mathrm{Th17\ oranı} = \frac{\mathrm{IL\!-\!17A^+\ CD4^+\ T\ hücreleri}}{\mathrm{toplam\ canlı\ CD4^+\ T\ hücreleri}} \times 100 \]

DON ilipunguza Th17 proportion, Il17a mRNA na IL-17A protein.

Neutralization ya IL-17

Secukinumab ilitumika kukata IL-17 pathway moja kwa moja:

\[ 20\ \mathrm{mg/kg/gün,\ intraperitoneal} \]

.

Kulingana na supplementary figure legend, IL-17 neutralization ilipunguza kidney injury na fibrosis. Hii inaunga mkono kwamba Th17/IL-17 si secondary change tu inayofuata HBP inhibition. Hata hivyo, maelezo ya secukinumab experiment yaliachwa kwenye supplementary material ambayo haipo katika PDF kuu.

Kwa nini STAT3 ilichaguliwa kuwa molecule kuu?

STAT3 ni transcription factor inayobadilisha extracellular cytokine na growth factor signals kuwa gene expression ndani ya nucleus. Ni regulator muhimu wa Th17 differentiation na inaweza pia kuathiri expression ya chemokines kama CXCL10.

Immunofluorescence iliripoti co-localization ya STAT3 signal na O-GlcNAc signal katika maeneo yale yale ya seli.

DON:

• ilipunguza STAT3 protein,
• ilipunguza phosphorylated STAT3,
• haikubadilisha STAT3 mRNA.

Hii inaonyesha regulation baada ya transcription, yaani post-translational level.

STAT3 inhibition

STAT3 inhibitor Stattic:

\[ 10\ \mathrm{mg/kg/gün,\ intraperitoneal} \]

ilitumika kwa panya na pia katika cell experiments.

STAT3 inhibition ilipunguza:

• CXCL10 transcription,
• CD4+ T-cell infiltration,
• Th17 differentiation,
• fibrosis markers.

Hii inaunga mkono STAT3 kama functional intermediate node kati ya HBP/O-GlcNAc signaling na immune fibrosis.

Protein half-life ilipimwaje?

Katika HK-2 cells, cycloheximide (CHX) ilitumika kusimamisha new protein synthesis. Cells zilichunguzwa saa 0, 3, 6, 9, 12 na 24 ili kuona existing STAT3 protein inapotea kwa kasi gani.

Protein decay inaweza kuelezwa kwa:

\[ P(t) = P_0 e^{-kt} \]

\[ t_{1/2} = \frac{\ln 2}{k} \]

Ambapo:

• P(t) ni STAT3 amount katika time t,
• P₀ ni initial STAT3 amount,
• k ni degradation rate constant,
• t_1/2 ni protein half-life.

Milinganyo hii haikutolewa kwenye makala; imeongezwa kueleza logic ya CHX half-life experiment.

DON ilifanya STAT3 ipotee kwa kasi na half-life ikawa fupi.

DON ilipotumika, STAT3 protein iliripotiwa kupotea kwa kasi zaidi na half-life yake kuwa fupi.

T717 site ilitambuliwaje?

Watafiti walitabiri sites sita zinazoweza kuwa za O-GlcNAc kwenye STAT3 na kutengeneza mutant proteins zenye amino acid substitutions kwenye sites hizo.

T717, S719, T721 na S727 mutations zilipunguza STAT3 O-GlcNAc. Lakini ni T717 mutation pekee ilipunguza half-life ya STAT3 kwa uwazi.

Kwa hiyo utafiti unapendekeza:

• sites zaidi ya moja zinaweza kupata O-GlcNAc,
• lakini T717 ndiyo determinant kubwa ya protein stability.

inapendekeza.

Ubiquitin–proteasome system

Sel huwaweka ubiquitin labels kwenye proteins zilizoharibika au zilizomaliza kazi ili zipelekwe kwenye proteasome.

\[ \mathrm{STAT3} \xrightarrow{\mathrm{E3\ ligaz}} \mathrm{STAT3\!-\!Ub_n} \xrightarrow{\mathrm{proteazom}} \mathrm{parçalanmış\ ürünler} \]

Proteasome ilipokandamizwa na MG132, effect ya DON ya kupunguza normal STAT3 ilibadilishwa. Katika T717A mutant, MG132 haikuonyesha pattern ileile.

T717 mutation iliongeza STAT3 ubiquitination. Ubiquitination ya T717A mutant haikubadilishwa sana na interventions zinazoongeza au kupunguza O-GlcNAc. Hii inaunga mkono T717 kuwa regulatory point kuu kati ya O-GlcNAc na ubiquitination.

SMURF1 iligunduliwaje?

Co-immunoprecipitation, SDS-PAGE na mass spectrometry zilitumika kulinganisha proteins zinazofunga normal STAT3 na T717A mutant.

Moja ya proteins zilizofunga T717A STAT3 zaidi ilikuwa E3 ubiquitin ligase SMURF1.

Katika majaribio ya baadaye:

• physical interaction ya STAT3 na SMURF1 ilithibitishwa kwa co-IP,
• SMURF1 overexpression ilipunguza STAT3 protein,
• ilipunguza CXCL10 mRNA,
• kuongeza O-GlcNAc kulipunguza effect ya SMURF1,
• T717A mutation iliongeza SMURF1–STAT3 binding.

Modeli ya molekuli iliyopendekezwa ni:

STAT3 ikiwa stable huathirije fibrosis?

STAT3 inayobaki muda mrefu ndani ya seli inaweza kuendeleza profibrotic transcription program katika renal tubular cells. Utafiti unapendekeza outcomes mbili kuu:

1. CXCL10 increase: CXCR3-bearing CD4+ T cells huvutwa kwenda figoni.
2. Th17 differentiation: CD4+ T cells zinazofika figoni huendelea kuwa IL-17A-producing Th17 phenotype.

Mekanizimu hizi zinakamilishana. Ya kwanza huleta immune cell kwenye figo iliyojeruhiwa; ya pili huifanya iwe immune subtype inayoongeza fibrosis.

Rutin hydrate ilipatikanaje?

Structure-based virtual screening ilifanywa kwa kutumia 3D structure ya STAT3 T717 region. Compound library ilikuwa na 3.158 substances.

Mwishoni:

• candidates 38 zilichaguliwa,
• top three zilipelekwa kwenye experimental testing.

Hizi zilikuwa:

1. Inositol nicotinate
2. Saquinavir
3. Rutin hydrate

Rutin hydrate ni flavonoid. Dai kuu ni kwamba haionyeshi tu general antioxidant au anti-inflammatory effect; inalenga STAT3 T717 O-GlcNAc modification.

Rutin hydrate ni flavonoid. Dai kuu la utafiti ni kwamba compound hii haionyeshi tu general antioxidant au inflammation-reducing properties, bali inalenga O-GlcNAc modification ya STAT3 katika T717 region.

Athari ya rutin hydrate katika cell experiments

Rutin hydrate:

• ilipunguza O-GlcNAc ya normal STAT3,
• ilipunguza STAT3 protein level,
• haikubadilisha STAT3 mRNA,
• ilipunguza CXCL10 expression.

Kutokuwepo kwa effect hii kwenye T717A mutant kulitafsiriwa kama support ya specificity kwa T717.

Hata hivyo, main text haijaripoti direct quantitative biophysical binding test kama surface plasmon resonance au isothermal titration calorimetry. Findings zinategemea virtual modeling, mutation dependence, immunoprecipitation na protein expression.

Athari ya rutin hydrate katika animal experiment

UUO mice walipewa orally:

\[ 5\ \mathrm{mg/kg/gün\ rutin\ hidrat} \]

. Figure 6 legend inasema treatment ilikuwa wiki moja.

Baada ya rutin hydrate:

• STAT3 na p-STAT3 zilipungua,
• serum creatinine na BUN ziliboreka,
• KIM-1 marker ilipungua,
• CD4+ T-cell infiltration ilipungua,
• Th17 proportion ilipungua,
• HE, PAS, Sirius Red na Masson stains zilionyesha kupungua kwa tissue injury na collagen deposition.

Hii inafanya rutin hydrate kuwa research candidate. Lakini single short animal dose kuwa effective hakumaanishi itakuwa safe au effective kwa binadamu.

Kielelezo 1 kinaonyesha nini?

Kulingana na Figure 1 legend, utafiti:

• ulilinganisha OGT, OGA na HBP enzymes katika human databases,
• ulifanya O-GlcNAc immunohistochemistry katika human CKD kidney biopsies 20,
• ulionyesha workflow ya UUO na folic acid models,
• ulichunguza HBP enzymes kwa RT-qPCR, Western blot na IHC katika modeli zote mbili.

PDF iliyopakiwa haina actual image panels za Figure 1; ina legend tu. Kwa hiyo staining intensity, band images, scatter distributions na error bars haziwezi kutathminiwa kwa macho kwa kujitegemea.

Kielelezo 2 kinaonyesha nini?

Figure 2 legend inaonyesha:

• uhusiano wa HBP enzymes na GFR,
• athari ya DON kwenye O-GlcNAc,
• collagen I na α-SMA Western blots,
• BUN na creatinine,
• PAS, Masson na IHC images.

Kwa baadhi ya kidney function measurements n = 4, na kwa tissue analyses mara nyingi n = 5.

Kielelezo 3 kinaonyesha nini?

Figure 3 inajumuisha:

• RNA-seq differential analysis,
• genes 97 zilivorejeshwa na DON,
• GO na KEGG enrichment,
• CD4 na CXCL10 measurements,
• AMG487 experiments,
• Th17 flow cytometry,
• IL-17A mRNA na protein results.

inavikusanya pamoja.

Kielelezo 4 kinaonyesha nini?

Figure 4 inachunguza:

• STAT3–O-GlcNAc co-localization,
• STAT3 protein vs mRNA,
• CHX half-life experiment,
• STAT3 site mutations,
• MG132 proteasome experiment,
• STAT3 ubiquitination.

vilichunguzwa.

Kielelezo 5 kinaonyesha nini?

Figure 5 inaonyesha identification ya SMURF1 na interaction yake na STAT3 kupitia:

• mass spectrometry,
• co-immunoprecipitation,
• SMURF1 overexpression,
• CXCL10 measurement,
• ubiquitination experiments za normal STAT3 na T717A mutant.

inajumuisha.

Kielelezo 6 kinaonyesha nini?

Figure 6 inafupisha athari ya rutin hydrate kwenye:

• STAT3 O-GlcNAc modification,
• T717A mutant,
• CXCL10 na CXCR3 expression,
• creatinine na BUN,
• KIM-1 na CD4 expression,
• kidney histology,
• Th17 proportion.

inafupisha athari zake.

Hata hivyo, actual experimental panels za Figure 1–6 hazipo kwenye PDF ya kurasa 36. PDF inaishia na figure legends baada ya results text. Kwa hiyo magnitude, distribution na raw image quality zinaweza kutathminiwa tu kutokana na legends.

Nguvu za utafiti

• Multilayer experimental design: Human data, human kidney tissue, animal models mbili na cell lines mbili zimetumika.
• Fibrosis models mbili: Findings hazitegemei UUO pekee.
• Multiple pathway interventions: HBP, CXCR3, STAT3 na IL-17 zinalengwa tofauti.
• Transcriptome analysis: Immune pattern pana zaidi imechunguzwa badala ya genes chache zilizochaguliwa.
• Mutation experiments: T717 site imejaribiwa.
• Protein degradation mechanism: CHX, MG132 na ubiquitin experiments zimetumika pamoja.
• E3 ligase identification: SMURF1 imechunguzwa kwa mass spectrometry na co-IP.
• Mechanism-to-compound transition: Rutin hydrate imejaribiwa baada ya structure-based screening.
• Human kidney tissue validation: Mechanism haitegemei cells au mice pekee.
• Data-sharing plan: RNA-seq imeorodheshwa kama BioProject PRJNA14422936.

Mapungufu ya utafiti

• Hakuna peer review: Ni preprint.
• Si clinical trial: Hakuna CKD patient aliyepewa DON, AMG487, Stattic, secukinumab au rutin hydrate.
• Small animal groups: Mara nyingi n = 5; baadhi ya kidney function analyses n = 4.
• Male mice pekee: Sex-related differences hazijachunguzwa.
• Short-term models: UUO siku 7, FA siku 28.
• Haziiwakilishi kikamilifu human CKD: Ugonjwa wa binadamu hukua kwa miaka na comorbid factors nyingi.
• Limited genetic HBP validation: Kidney-specific GFPT1 deletion/overexpression haijaonyeshwa.
• Pharmacological specificity issue: Effects zote za DON hazijathibitishwa kuwa GFPT1/HBP-only.
• OGT/OGA activity haijapimwa: Expression kutobadilika si sawa na activity kutobadilika.
• Human sample characteristics hazijakamilika: Umri, sex, CKD cause, stage, diabetes na treatments hazijaelezwa kwa kina.
• Figures hazipo kwenye PDF: Legends tu.
• Supplementary methods hazipo: Maandishi yanarejea supplement ambayo haijapakiwa.
• Randomization/blinding hazijaelezwa: Assignment ya animals na blinded histology hazijaelezwa.
• Sample-size calculation haipo. Hakuna msingi wa kitakwimu wa idadi ya wanyama uliotolewa.
• Experimental replication reporting ni limited: Experiments zilirudiwa angalau mara mbili, lakini biological vs technical replicates hazijaelezwa.
• Statistical reporting ni limited: Mainly one-way ANOVA, mean ± SEM na star p thresholds.
• Effect sizes na confidence intervals nyingi hazipo. Kwa matokeo mengi, tofauti kamili za namba, confidence intervals na raw data hazijatolewa katika main text.
• Multiple-comparison correction haijaelezwa. Genes, proteins na treatment groups nyingi zilitathminiwa.
• Rutin hydrate dose-response haipo. Ufanisi na toxicity ya doses tofauti hazikulinganishwa.
• Pharmacokinetic data haipo. Absorption, blood level, kidney-tissue penetration na half-life havikuchunguzwa.
• Long-term safety haijulikani. Chronic use, liver effects, drug interactions na immunological adverse effects hazijachunguzwa.
• Direct binding test ni limited: Hakuna quantitative biophysical test.
• Hakuna comparison na standard treatment. Rutin hydrate haikulinganishwa na current CKD au antifibrotic approaches.
• Editorial issues zipo katika figure/supplement numbering. Baadhi ya figure legends zinarudia panel letters na kuacha experimental details bila ukamilifu.

Utafiti unasema nini?

• General protein O-GlcNAc iliongezeka katika human CKD tissue na mouse models mbili.
• Hii iliambatana na kuongezeka kwa HBP enzymes.
• OGT na OGA expression hazikubadilika kwa uwazi.
• DON suppression ya HBP ilipunguza fibrosis na kidney dysfunction kwa mice.
• HBP/O-GlcNAc signaling huvuta CD4+ T cells kupitia CXCL10–CXCR3.
• Signal hii inahusishwa na Th17 differentiation na IL-17A production.
• STAT3 ilitambuliwa kama central molecule.
• STAT3 T717 O-GlcNAc iliongeza protein half-life.
• O-GlcNAc ilipunguza SMURF1 binding na STAT3 ubiquitination.
• Rutin hydrate ilipunguza STAT3 O-GlcNAc katika cells.
• Rutin hydrate ilipunguza fibrosis na immune infiltration katika short-term UUO model.

Utafiti haussemi nini?

• Hauonyeshi rutin hydrate inatibu CKD kwa binadamu.
• Hauonyeshi vyakula au supplements zenye rutin zinazuia kidney fibrosis.
• Haupeani effective/safe human dose.
• Hauonyeshi rutin hydrate inazuia dialysis au kidney failure.
• Hauonyeshi HBP ni active sawa katika kila CKD type.
• Hauthibitishi OGT/OGA hazina role katika CKD.
• Hauonyeshi STAT3 ndiyo O-GlcNAc target pekee katika fibrosis.
• Hauonyeshi Th17 ndiyo immune cell pekee.
• Hauonyeshi DON ni safe antifibrotic therapy kwa binadamu.
• Hauthibitishi moja kwa moja highly selective binding ya rutin hydrate kwa T717.
• Hauthibitishi short-term mouse improvement itazuia long-term CKD progression.

Umuhimu kwa historia

Renal fibrosis research kwa muda mrefu imejikita kwenye TGF-β, fibroblast activation, hemodynamic stress na inflammatory cytokines. Miaka ya karibuni imeonyesha kwamba metabolic programs za injured renal cells pia zinaweza kuongoza fibrosis.

Utafiti huu unaunganisha metabolic reprogramming si na energy use tu, bali na uwezo wa metabolic flux kubadilishwa kuwa immune-cell behavior kupitia protein modification.

Umuhimu kwa sasa

Mchango mkuu wa dhana ni kuona renal fibrosis si kama “metabolic disease” au “inflammatory disease” tofauti, bali integrated immunometabolic disorder.

HBP:

• huhisi nutrient status,
• hubadilisha UDP-GlcNAc production,
• hudhibiti STAT3 protein stability,
• huathiri chemokine production na T-cell migration,
• huongeza Th17 response na fibrosis.

Pathway kama hii inaweza kutoa fursa ya kulenga communication kati ya renal tubular cells, T lymphocytes na fibrotic microenvironment badala ya cell type moja.

Umuhimu kwa siku zijazo

Tafiti zaidi zinapaswa kujibu:

• Upstream signal gani huanzisha HBP katika CKD?
• Hypoxia, ER stress au specific cytokines huamilishaje HBP?
• Ni profibrotic proteins gani nyingine zinastabilize kwa O-GlcNAc?
• T717 modification inaweza kuthibitishwa direct na quantitatively katika human kidney tissue?
• Kidney-cell-specific genetic HBP suppression hupunguza fibrosis?
• Real kidney-tissue concentration ya rutin hydrate ni kiasi gani?
• Rutin hydrate ni effective katika slower long-term CKD models?
• Long-term effects kwa immune system, liver na other organs ni zipi?
• More selective/potent T717-targeting derivatives zinaweza kutengenezwa?
• Safe human dose range inaweza kupatikana?

Ina maana gani kwa mgonjwa na maisha ya kila siku?

Utafiti hautoi pendekezo kwa wagonjwa wa figo kutumia vyakula au supplements zenye rutin kama tiba. Rutin hydrate imetathminiwa tu kwenye cell culture na experimental mice.

Kwa CKD patients, supplements na herbal products zinaweza:

• kujikusanya mwilini kulingana na kidney function,
• kuingiliana na prescription drugs,
• kuwa na effects tofauti kulingana na purity na dose,
• kuwa na potassium au substances nyingine.

Kwa hiyo, utafiti si clinical evidence ya kuanza rutin supplement bila ushauri. Toxicity, pharmacokinetics, dose-finding na controlled clinical trials zinahitajika kabla ya human treatment.

Mbinu na Matokeo ya Utafiti

Muhtasari wa kiufundi wa mbinu za utafiti

Pharmacological interventions

Vifaa vikuu vya cell experiments

Technical logic ya experimental chain

1. HBP na O-GlcNAc increase ilionyeshwa katika human na mouse kidney.
2. HBP suppression ilijaribiwa kwa fibrosis na kidney function outcomes.
3. RNA-seq ilitambua immune response na chemokine axis.
4. CXCR3, STAT3 na IL-17 zilijaribiwa kwa interventions tofauti.
5. STAT3 half-life ilionyeshwa kutegemea O-GlcNAc state.
6. Mutations zilitambua T717 kama functional site.
7. SMURF1 ilipendekezwa kuwa E3 ligase ya STAT3 degradation.
8. Virtual screening ilichagua T717-targeting candidates.
9. Rutin hydrate ilithibitishwa katika cells na mice.

Modeli kuu ya molekuli

Muhtasari wa intervention results

Muhtasari wa rutin hydrate screening

Matokeo muhimu zaidi ya kiufundi

Pendekezo muhimu zaidi la kisayansi ni kwamba metabolic signaling na immune response katika renal fibrosis zinaweza kuunganishwa kupitia mlolongo mmoja wa molekuli.

HBP increase haibadilishi sugar metabolism tu. Kwa kuongeza UDP-GlcNAc, huongeza chemical mark kwenye STAT3 T717, huikinga STAT3 dhidi ya cellular degradation na kuifanya ibaki active kwa muda mrefu.

Stable STAT3 huongeza CXCL10 production, CD4+ T-cell migration na Th17 response. Hivyo short-term metabolic change inaweza kugeuka kuwa self-sustaining immune-fibrotic microenvironment.

Rutin hydrate imewasilishwa kama research tool na candidate compound inayoweza kukata chain katika kiwango cha T717 modification. Lakini bado haipaswi kuchukuliwa kama CKD drug.

Maelezo ya Chanzo na Mbinu

Maudhui haya yanategemea utafiti wa Hongxia Yang, Bin Liu, Guangtao Li, Dan Zhang, Shangguo Wang, Zehua Zhang, Xiaodong Zhao, Jiaxin Liu, Qianhui Li, Yifan Song, Yang Tan, Shuyue Ma, Honglan Zhou, Yishu Wang na Yanghe Zhang wenye kichwa “Hexosamine Biosynthesis Pathway Driven O-GlcNAcylation of STAT3 Orchestrates Renal Fibrosis via a T cell Mediated Immune Pathway in CKD”.

Utafiti ni preclinical mechanism and drug-candidate discovery preprint unaochanganya human kidney tissue, public human expression data, UUO na folic acid nephropathy models katika male BALB/c mice, HK-2 na 293T cells, RNA sequencing, mutation, immunoprecipitation, ubiquitination na structure-based virtual screening.

Maandishi yana “This preprint research paper has not been peer reviewed” na “Preprint not peer reviewed”. Kwa hiyo, utafiti haujapitia peer review na PDF haithibitishi final journal acceptance.

Animal experiments ziliripotiwa kuidhinishwa na Jilin University College of Basic Medical Sciences IACUC kwa protocol 2025-530. Human kidney tissue studies zilipata approval 2024-1151 kutoka First Hospital of Jilin University ethics committee na written informed consent iliripotiwa.

RNA-seq data ziliripotiwa kushirikiwa katika NCBI Sequence Read Archive kama BioProject PRJNA14422936. Data nyingine zilisemwa kupatikana katika makala, supplementary files au kutoka corresponding author kwa reasonable request.

Utafiti ulifadhiliwa na National Natural Science Foundation of China, Jilin Province Natural Science Foundation na institutional funds nyingine zilizoorodheshwa. Waandishi hawakuripoti conflict of interest.

PDF ya kurasa 36 haina actual images/graph panels za Figures 1–6; ina figure legends tu. Main methods section inasema remaining methods zipo kwenye supplementary material, lakini material hiyo haipo kwenye file iliyopakiwa.

Rutin hydrate imetathminiwa tu katika cell culture na short-term mouse experiments. Hakuna human dose, pharmacokinetic, safety, efficacy au clinical outcome data. Utafiti hauungi mkono kuanza rutin supplements, kusimamisha standard CKD treatment au kutumia rutin hydrate kama tiba.

Neno “first-in-class targeted inhibitor” ni designation ya waandishi kulingana na preclinical data. Halimaanishi clinically approved drug, proven treatment au demonstrated human target specificity.

Makala hii imeandaliwa tu kutokana na mbinu, figure legends, experimental results na interpretations za waandishi katika PDF iliyopakiwa. Hakuna clinical efficacy, human dose, treatment superiority, safety guarantee au dai la kuponya kidney disease lililoongezwa bila kuwa katika PDF.